ESTA — Establishment Labs Holdings Inc.

Establishment Labs (ESTA) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $64.6 million, up 45.2% year-over-year; U.S. Motiva revenue was $17.3 million.
• 2025 Total Revenue: $211.1 million, a 27.2% increase from 2024.
• Gross Margin: 70.5% in Q4, consistent with previous quarters; 330 basis point increase for the year.
• Net Loss: $3.9 million in Q4, down 79% from Q4 2024.
• Adjusted EBITDA: Positive $5.5 million in Q4, a significant improvement from a loss of $13.1 million in Q4 2024.
• Cash Position: $75.6 million at year-end, with no need for additional capital.

2. Strategic Updates and Business Highlights

• Market Position: Established strong presence in the U.S. breast augmentation market with approximately 20% market share.
• Innovation: Continued investment in R&D with a focus on minimally invasive procedures (Preserve and Mia) and new product launches.
• Sales Force Expansion: Plans to add up to 15 new sales representatives in 2026 to drive U.S. market penetration.
• International Growth: Strong performance in European direct markets (20% growth) and stabilization in Latin America, particularly in Argentina.
• FDA Submissions: Submitted Motiva implants for approval in reconstruction, expected to double the addressable market.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: $264 million to $266 million, representing a growth of 25.1% to 26% over 2025.
• Gross Margin Expectations: Anticipated increase of 200 to 300 basis points.
• Cash Flow: Expected to be cash flow positive in 2026, with free cash use projected to be less than half of 2025 levels.

4. Bad News, Challenges, or Points of Concern

• Market Competition: The company faces competition from established brands in the breast augmentation market, which may impact market share growth.
• Regulatory Risks: Dependence on FDA approvals for new products, particularly in reconstruction, which could delay market entry and revenue generation.
• International Market Fluctuations: Variability in distributor markets, particularly in China, which has faced challenges but is showing signs of recovery.

5. Notable Q&A Insights

• Minimally Invasive Portfolio: Strong early interest in Preserve, with expectations that it could significantly expand the market for breast augmentation procedures.
• Sales Strategy: Focus on hiring experienced sales representatives from the aesthetic sector to drive growth and penetration in the U.S. market.
• Reconstruction Market: Anticipated to be a major growth driver in 2027, with plans to expand the sales force to support hospital contracts and larger networks.
• Market Health: Overall demand for breast augmentation procedures remains strong, with positive feedback from surgeons and patients.
• Future Growth: Potential for Preserve to contribute significantly to revenue, with estimates suggesting it could represent up to 50% of U.S. revenues by 2027.

This summary encapsulates the key financial metrics, strategic initiatives, future outlook, and challenges faced by Establishment Labs as discussed in their Q4 2025 earnings call.